Symbols / LEGN Stock $22.77 -3.35% Legend Biotech Corporation

Healthcare • Biotechnology • United States • NMS
LEGN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Ying Huang Ph.D.
Exch · Country NMS · United States
Market Cap 4.21B
Enterprise Value 8.18B
Income -296.80M
Sales 1.03B
FCF (ttm) -133.99M
Book/sh 5.42
Cash/sh 2.56
Employees 2,900
Insider 10d —
IPO Jun 05, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 19.80
PEG —
P/S 4.09
P/B 4.20
P/C —
EV/EBITDA -64.36
EV/Sales 7.95
Quick Ratio 1.88
Current Ratio 1.96
Debt/Eq 41.28
LT Debt/Eq —
EPS (ttm) -1.62
EPS next Y 1.15
EPS Growth —
Revenue Growth 64.20%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2026-03-10
ROA -5.01%
ROE -29.06%
ROIC —
Gross Margin 20.03%
Oper. Margin -6.72%
Profit Margin -28.85%
Shs Outstand 184.96M
Shs Float 163.25M
Insider Own 1.32%
Instit Own 50.36%
Short Float 26.43%
Short Ratio 13.06
Short Interest 19.22M
52W High 45.30
vs 52W High -49.73%
52W Low 16.24
vs 52W Low 40.21%
Beta 0.08
Impl. Vol. 29.60%
Rel Volume 0.69
Avg Volume 2.05M
Volume 1.42M
Target (mean) $57.23
Tgt Median $61.00
Tgt Low $21.00
Tgt High $86.00
# Analysts 16
Recom Buy
Prev Close $23.56
Price $22.77
Change -3.35%
About

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$57.24
Mean price target
2. Current target
$22.77
Latest analyst target
3. DCF / Fair value
$-13.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$22.77
Low
$21.00
High
$86.00
Mean
$57.24

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-21 reit HC Wainwright & Co. Buy → Buy $50
2026-04-15 reit HC Wainwright & Co. Buy → Buy $50
2026-03-11 main Morgan Stanley Overweight → Overweight $49
2026-03-11 main RBC Capital Outperform → Outperform $62
2026-02-04 main Barclays Overweight → Overweight $80
2026-01-22 main HC Wainwright & Co. Buy → Buy $50
2026-01-22 down TD Cowen Buy → Hold $21
2026-01-20 main RBC Capital Outperform → Outperform $66
2026-01-07 init Oppenheimer — → Outperform $75
2025-12-17 main Cantor Fitzgerald Overweight → Overweight $74
2025-12-12 main Morgan Stanley Overweight → Overweight $50
2025-12-08 main UBS Buy → Buy $48
2025-11-13 main Barclays Overweight → Overweight $90
2025-11-13 main RBC Capital Outperform → Outperform $74
2025-11-13 main Cantor Fitzgerald Overweight → Overweight $75
2025-10-17 main HC Wainwright & Co. Buy → Buy $60
2025-10-09 main JP Morgan Overweight → Overweight $76
2025-08-25 main JP Morgan Overweight → Overweight $78
2025-08-12 main RBC Capital Outperform → Outperform $77
2025-08-12 main Morgan Stanley Overweight → Overweight $83
News
RSS: Latest LEGN news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1,028.90
+64.02%
627.30
+120.03%
285.10
+143.66%
117.00
Operating Revenue
1,028.60
+65.64%
621.00
+117.89%
285.00
+144.26%
116.68
Cost Of Revenue
408.10
+73.96%
234.60
+62.69%
144.20
+120.61%
65.36
Reconciled Cost Of Revenue
408.10
+73.96%
234.60
+62.69%
144.20
+120.61%
65.36
Gross Profit
620.80
+58.09%
392.70
+178.71%
140.90
+172.84%
51.64
Operating Expense
757.30
+7.85%
702.20
+4.96%
669.00
+31.88%
507.26
Research And Development
414.70
+0.29%
413.50
+8.19%
382.20
+13.87%
335.65
Selling General And Administration
341.60
+20.15%
284.30
+41.44%
201.00
+15.49%
174.05
Selling And Marketing Expense
205.80
+39.53%
147.50
+56.58%
94.20
+0.84%
93.42
General And Administrative Expense
135.80
-0.73%
136.80
+28.09%
106.80
+32.46%
80.63
Other Gand A
135.80
-0.73%
136.80
+28.09%
106.80
+32.46%
80.63
Other Operating Expenses
1.00
-77.27%
4.40
-94.87%
85.80
+3625.06%
-2.43
Total Expenses
1,165.40
+24.40%
936.80
+15.20%
813.20
+42.01%
572.62
Operating Income
-136.50
+55.90%
-309.50
+41.39%
-528.10
-15.91%
-455.62
Total Operating Income As Reported
-136.50
+55.90%
-309.50
+41.39%
-528.10
—
EBITDA
-232.30
-101.82%
-115.10
+76.02%
-479.90
-15.21%
-416.54
Normalized EBITDA
-63.50
+71.70%
-224.40
+50.32%
-451.70
-3.12%
-438.04
Reconciled Depreciation
28.90
+35.05%
21.40
+15.68%
18.50
+0.59%
18.39
EBIT
-261.20
-91.36%
-136.50
+72.61%
-498.40
-14.59%
-434.93
Total Unusual Items
-168.80
-254.44%
109.30
+487.59%
-28.20
-231.14%
21.50
Total Unusual Items Excluding Goodwill
-168.80
-254.44%
109.30
+487.59%
-28.20
-231.14%
21.50
Special Income Charges
—
-4.42
0.00
0.00
Impairment Of Capital Assets
—
4.42
0.00
0.00
Write Off
—
4.42
0.00
0.00
Net Income
-296.80
-67.68%
-177.00
+65.85%
-518.30
-16.12%
-446.35
Pretax Income
-282.60
-78.75%
-158.10
+69.61%
-520.20
-16.71%
-445.72
Net Non Operating Interest Income Expense
18.70
-52.78%
39.60
+21.10%
32.70
+1350.96%
-2.61
Interest Expense Non Operating
21.40
-0.93%
21.60
-0.92%
21.80
+101.93%
10.80
Net Interest Income
18.70
-52.78%
39.60
+21.10%
32.70
+1350.96%
-2.61
Interest Expense
21.40
-0.93%
21.60
-0.92%
21.80
+101.93%
10.80
Interest Income Non Operating
40.10
-34.48%
61.20
+12.29%
54.50
+566.10%
8.18
Interest Income
40.10
-34.48%
61.20
+12.29%
54.50
+566.10%
8.18
Other Income Expense
-164.80
-247.41%
111.80
+550.81%
-24.80
-298.24%
12.51
Other Non Operating Income Expenses
4.00
+60.00%
2.50
-26.47%
3.40
+137.81%
-8.99
Gain On Sale Of Security
-168.80
-254.44%
109.30
+487.59%
-28.20
-231.14%
21.50
Tax Provision
14.20
-24.87%
18.90
+1094.74%
-1.90
-404.00%
0.62
Tax Rate For Calcs
0.00
+0.00%
0.00
+5650.27%
0.00
-98.26%
0.00
Tax Effect Of Unusual Items
-35.45
-254.44%
22.95
+22384.72%
-0.10
-102.28%
4.52
Net Income Including Noncontrolling Interests
-296.80
-67.68%
-177.00
+65.85%
-518.30
-16.12%
-446.35
Net Income From Continuing Operation Net Minority Interest
-296.80
-67.68%
-177.00
+65.85%
-518.30
-16.12%
-446.35
Net Income From Continuing And Discontinued Operation
-296.80
-67.68%
-177.00
+65.85%
-518.30
-16.12%
-446.35
Net Income Continuous Operations
-296.80
-67.68%
-177.00
+65.85%
-518.30
-16.12%
-446.35
Normalized Income
-163.45
+37.93%
-263.35
+46.28%
-490.20
-5.80%
-463.34
Net Income Common Stockholders
-296.80
-67.68%
-177.00
+65.85%
-518.30
-16.12%
-446.35
Diluted EPS
-1.62
-68.75%
-0.96
+67.35%
-2.94
-5.00%
-2.80
Basic EPS
-1.62
-68.75%
-0.96
+67.35%
-2.94
-5.00%
-2.80
Basic Average Shares
184.32
+0.80%
182.85
+3.84%
176.08
+10.71%
159.04
Diluted Average Shares
184.32
+0.80%
182.85
+3.84%
176.08
+10.71%
159.04
Diluted NI Availto Com Stockholders
-296.80
-67.68%
-177.00
+65.85%
-518.30
-16.12%
-446.35
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
1,733.70
+3.80%
1,670.20
-9.65%
1,848.61
+38.89%
1,330.96
Current Assets
1,247.10
-2.87%
1,283.90
-14.28%
1,497.80
+36.27%
1,099.12
Cash Cash Equivalents And Short Term Investments
948.60
-15.50%
1,122.60
-14.22%
1,308.72
+27.60%
1,025.65
Cash And Cash Equivalents
901.90
+214.58%
286.70
-77.56%
1,277.71
+62.55%
786.03
Cash Financial
901.90
+214.58%
286.70
—
—
Other Short Term Investments
46.70
-94.41%
835.90
+2596.10%
31.00
-87.06%
239.62
Receivables
250.30
+100.08%
125.10
-20.35%
157.06
+252.83%
44.52
Accounts Receivable
13.10
+104.69%
6.40
-93.60%
100.04
+111056.67%
0.09
Gross Accounts Receivable
—
—
—
0.09
Allowance For Doubtful Accounts Receivable
—
—
—
—
Other Receivables
229.10
+100.79%
114.10
+102.82%
56.26
+35.52%
41.51
Taxes Receivable
8.10
+76.09%
4.60
+541.56%
0.72
-48.64%
1.40
Accrued Interest Receivable
—
0.00
-100.00%
0.05
-96.90%
1.52
Inventory
32.00
+33.89%
23.90
+22.99%
19.43
+87.69%
10.35
Raw Materials
24.10
+37.71%
17.50
+33.03%
13.15
+88.22%
6.99
Work In Process
1.10
-75.00%
4.40
+47.16%
2.99
+333.33%
0.69
Finished Goods
6.80
+240.00%
2.00
-39.17%
3.29
+22.92%
2.67
Prepaid Assets
14.60
+18.70%
12.30
+0.56%
12.23
-29.42%
17.33
Restricted Cash
—
0.07
-80.39%
0.36
-71.89%
1.27
Other Current Assets
1.60
—
—
—
Total Non Current Assets
486.60
+25.96%
386.30
+10.12%
350.81
+51.31%
231.84
Net PPE
402.00
+99.40%
201.60
+6.29%
189.68
+17.32%
161.67
Gross PPE
455.50
+85.69%
245.30
+9.18%
224.68
+20.23%
186.88
Accumulated Depreciation
-53.50
-22.43%
-43.70
-24.85%
-35.00
-38.85%
-25.21
Properties
0.00
0.00
0.00
0.00
Land And Improvements
5.60
-15.15%
6.60
-6.79%
7.08
-2.28%
7.25
Buildings And Improvements
319.60
+134.48%
136.30
+97.08%
69.16
+38.43%
49.96
Machinery Furniture Equipment
64.30
+24.13%
51.80
+13.90%
45.48
-1.68%
46.26
Construction In Progress
14.70
+206.25%
4.80
+37.54%
3.49
-76.88%
15.10
Other Properties
28.70
+17.14%
24.50
-67.91%
76.35
+64.74%
46.35
Leases
22.60
+6.10%
21.30
-7.86%
23.12
+5.20%
21.97
Goodwill And Other Intangible Assets
74.60
-57.20%
174.30
+12.25%
155.28
+126.07%
68.69
Other Intangible Assets
74.60
-57.20%
174.30
+12.25%
155.28
+126.07%
68.69
Investments And Advances
5.00
+13.64%
4.40
+0.87%
4.36
0.00
Other Investments
—
—
—
0.00
Non Current Accounts Receivable
—
—
0.28
-27.85%
0.40
Non Current Prepaid Assets
5.00
-15.25%
5.90
+388.41%
1.21
+10.62%
1.09
Other Non Current Assets
—
0.10
-93.30%
1.49
—
Total Liabilities Net Minority Interest
731.60
+16.20%
629.60
+5.42%
597.24
+1.80%
586.65
Current Liabilities
636.40
+129.17%
277.70
+28.32%
216.42
-27.32%
297.79
Payables And Accrued Expenses
297.60
+31.97%
225.50
+40.79%
160.16
-29.37%
226.77
Payables
184.30
+11.02%
166.00
+63.43%
101.57
+31.08%
77.49
Accounts Payable
81.20
+118.28%
37.20
+23.77%
30.05
-5.17%
31.69
Other Payable
74.20
-28.17%
103.30
+67.61%
61.63
+82.28%
33.81
Current Accrued Expenses
113.30
+90.42%
59.50
+1.55%
58.59
-60.75%
149.28
Total Tax Payable
27.10
+12.45%
24.10
+159.50%
9.29
-13.91%
10.79
Current Debt And Capital Lease Obligation
326.50
+6702.08%
4.80
+51.18%
3.17
-10.89%
3.56
Current Debt
319.10
—
—
—
Other Current Borrowings
319.10
—
—
—
Current Capital Lease Obligation
7.40
+54.17%
4.80
+51.18%
3.17
-10.89%
3.56
Current Deferred Liabilities
11.30
-75.91%
46.90
-11.64%
53.08
+11668.96%
0.45
Current Deferred Revenue
11.30
-75.91%
46.90
-11.64%
53.08
+11668.96%
0.45
Other Current Liabilities
1.00
+100.00%
0.50
—
67.00
Total Non Current Liabilities Net Minority Interest
95.20
-72.95%
351.90
-7.59%
380.82
+31.83%
288.86
Long Term Debt And Capital Lease Obligation
87.20
-74.78%
345.80
+6.24%
325.50
+15.85%
280.97
Long Term Debt
—
301.20
+7.06%
281.33
+7.82%
260.93
Long Term Capital Lease Obligation
87.20
+95.52%
44.60
+0.98%
44.17
+120.42%
20.04
Non Current Deferred Liabilities
—
6.15
-88.86%
55.27
+621.60%
7.66
Non Current Deferred Revenue
—
6.15
-88.86%
55.27
+621.60%
7.66
Non Current Deferred Taxes Liabilities
—
—
—
—
Other Non Current Liabilities
8.00
+31.15%
6.10
+10792.86%
0.06
-75.97%
0.23
Stockholders Equity
1,002.10
-3.70%
1,040.60
-16.84%
1,251.37
+68.12%
744.31
Common Stock Equity
1,002.10
-3.70%
1,040.60
-16.84%
1,251.37
+68.12%
744.31
Capital Stock
0.10
+0.00%
0.10
+177.78%
0.04
+9.09%
0.03
Common Stock
0.10
+0.00%
0.10
+177.78%
0.04
+9.09%
0.03
Share Issued
369.89
+0.70%
367.30
+0.96%
363.82
+10.20%
330.13
Ordinary Shares Number
369.89
+0.70%
367.30
+0.96%
363.82
+10.20%
330.13
Additional Paid In Capital
2,750.30
+2.01%
2,696.00
+2.23%
2,637.12
+59.15%
1,657.02
Retained Earnings
-1,958.50
-17.86%
-1,661.70
-11.92%
-1,484.71
-53.62%
-966.46
Gains Losses Not Affecting Retained Earnings
122.20
+279.18%
-68.20
-253.94%
44.30
+201.98%
14.67
Other Equity Adjustments
—
—
—
-966.46
Total Equity Gross Minority Interest
1,002.10
-3.70%
1,040.60
-16.84%
1,251.37
+68.12%
744.31
Total Capitalization
1,002.10
-25.32%
1,341.80
-12.46%
1,532.70
+52.47%
1,005.24
Working Capital
610.70
-39.31%
1,006.20
-21.48%
1,281.38
+59.91%
801.33
Invested Capital
1,321.20
-1.54%
1,341.80
-12.46%
1,532.70
+52.47%
1,005.24
Total Debt
413.70
+18.00%
350.60
+6.67%
328.67
+15.51%
284.53
Net Debt
—
14.50
—
—
Capital Lease Obligations
94.60
+91.50%
49.40
+4.34%
47.34
+100.59%
23.60
Net Tangible Assets
927.50
+7.06%
866.30
-20.96%
1,096.09
+62.23%
675.63
Tangible Book Value
927.50
+7.06%
866.30
-20.96%
1,096.09
+62.23%
675.63
Available For Sale Securities
5.00
+13.64%
4.40
+0.87%
4.36
—
Dueto Related Parties Current
1.80
+28.57%
1.40
+133.33%
0.60
-50.00%
1.20
Foreign Currency Translation Adjustments
122.20
+279.18%
-68.20
-253.94%
44.30
+201.98%
14.67
Investmentin Financial Assets
5.00
+13.64%
4.40
+0.87%
4.36
0.00
Minimum Pension Liabilities
—
—
—
—
Other Equity Interest
88.00
+18.28%
74.40
+36.21%
54.62
+39.88%
39.05
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-100.20
+30.42%
-144.00
+63.39%
-393.30
-95.40%
-201.28
Cash Flow From Continuing Operating Activities
-100.20
+30.42%
-144.00
+63.39%
-393.30
-95.40%
-201.28
Net Income From Continuing Operations
-282.60
-78.75%
-158.10
+69.61%
-520.20
-16.71%
-445.72
Depreciation Amortization Depletion
28.90
+35.05%
21.40
+15.68%
18.50
+0.59%
18.39
Depreciation
28.90
+35.05%
21.40
+15.68%
18.50
+16.24%
15.92
Amortization Cash Flow
—
1.93
+0.36%
1.92
-22.29%
2.48
Depreciation And Amortization
28.90
+35.05%
21.40
+15.68%
18.50
+0.59%
18.39
Amortization Of Intangibles
—
1.93
+0.36%
1.92
-22.29%
2.48
Other Non Cash Items
-17.40
+54.33%
-38.10
-22.51%
-31.10
-466.44%
8.49
Stock Based Compensation
64.60
-6.24%
68.90
+44.44%
47.70
+38.91%
34.34
Provisionand Write Offof Assets
-3.00
-123.62%
12.70
+252.78%
3.60
-31.92%
5.29
Asset Impairment Charge
0.00
-100.00%
4.40
0.00
0.00
Operating Gains Losses
168.80
+254.44%
-109.30
-195.88%
114.00
+1112.43%
-11.26
Gain Loss On Investment Securities
—
—
85.80
+510.53%
-20.90
Unrealized Gain Loss On Investment Securities
0.00
0.00
+100.00%
-0.70
-18.04%
-0.59
Net Foreign Currency Exchange Gain Loss
168.80
+254.44%
-109.30
-487.59%
28.20
+207.89%
9.16
Gain Loss On Sale Of PPE
—
0.00
-99.12%
0.23
-53.01%
0.48
Change In Working Capital
-93.10
-605.98%
18.40
+125.31%
-72.70
-140.16%
181.03
Change In Receivables
-5.70
-106.08%
93.80
+194.75%
-99.00
-296.74%
50.32
Changes In Account Receivables
-5.70
-106.08%
93.80
+194.75%
-99.00
-296.74%
50.32
Change In Inventory
-4.50
+73.84%
-17.20
-35.43%
-12.70
+8.59%
-13.89
Change In Prepaid Assets
-126.80
-105.51%
-61.70
-609.20%
-8.70
+82.81%
-50.61
Change In Payables And Accrued Expense
80.50
+38.79%
58.00
+209.64%
-52.90
-127.59%
191.73
Change In Payable
80.50
+38.79%
58.00
+209.64%
-52.90
-127.59%
191.73
Change In Account Payable
44.40
+214.89%
14.10
+128.09%
-50.20
-169.29%
72.45
Change In Other Working Capital
-36.60
+32.84%
-54.50
-154.17%
100.60
+670766.67%
-0.01
Change In Other Current Assets
—
-4.56
-705.98%
0.75
-79.43%
3.66
Change In Other Current Liabilities
—
-0.06
+68.75%
-0.18
-7.98%
-0.16
Investing Cash Flow
709.60
+183.42%
-850.60
-1015.61%
92.90
+220.51%
-77.09
Cash Flow From Continuing Investing Activities
709.60
+183.42%
-850.60
-1015.61%
92.90
+220.51%
-77.09
Net PPE Purchase And Sale
-28.60
-102.84%
-14.10
+29.85%
-20.10
+3.95%
-20.93
Purchase Of PPE
-28.60
-102.84%
-14.10
+29.85%
-20.10
+3.95%
-20.93
Sale Of PPE
—
—
0.00
0.00
Capital Expenditure
-28.60
-102.84%
-14.10
+37.89%
-22.70
-1.91%
-22.27
Net Investment Purchase And Sale
777.00
+199.35%
-782.10
-466.32%
213.50
+632.26%
-40.11
Purchase Of Investment
-4,542.90
-67.50%
-2,712.20
+44.23%
-4,863.10
-642.49%
-654.97
Sale Of Investment
5,319.90
+175.63%
1,930.10
-61.98%
5,076.60
+725.65%
614.86
Net Intangibles Purchase And Sale
0.00
0.00
+100.00%
-2.60
-92.88%
-1.35
Purchase Of Intangibles
0.00
0.00
+100.00%
-2.60
-92.88%
-1.35
Net Other Investing Changes
-38.80
+28.68%
-54.40
+44.43%
-97.90
-565.76%
-14.71
Financing Cash Flow
-0.30
-105.26%
5.70
-99.28%
791.40
+109.38%
377.98
Cash Flow From Continuing Financing Activities
-0.30
-105.26%
5.70
-99.28%
791.40
+109.38%
377.98
Net Issuance Payments Of Debt
-3.60
+10.00%
-4.00
-5.26%
-3.80
-46.38%
-2.60
Issuance Of Debt
—
—
—
—
Repayment Of Debt
-3.60
+10.00%
-4.00
-5.26%
-3.80
-46.38%
-2.60
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
-3.60
+10.00%
-4.00
-5.26%
-3.80
-46.38%
-2.60
Net Long Term Debt Issuance
-3.60
+10.00%
-4.00
-5.26%
-3.80
-46.38%
-2.60
Net Common Stock Issuance
0.00
0.00
-100.00%
583.70
+54.56%
377.64
Proceeds From Stock Option Exercised
3.30
-65.98%
9.70
-95.41%
211.50
+7120.89%
2.93
Changes In Cash
609.10
+161.59%
-988.90
-301.41%
491.00
+392.96%
99.60
Effect Of Exchange Rate Changes
6.10
+390.48%
-2.10
-400.00%
0.70
+127.89%
-2.51
Beginning Cash Position
286.70
-77.56%
1,277.70
+62.56%
786.00
+14.09%
688.94
End Cash Position
901.90
+214.58%
286.70
-77.56%
1,277.70
+62.55%
786.03
Free Cash Flow
-128.80
+18.53%
-158.10
+62.00%
-416.00
-86.08%
-223.56
Common Stock Issuance
0.00
0.00
-100.00%
583.70
+54.56%
377.64
Interest Paid CFO
—
-1.77
-26.97%
-1.39
-164.52%
-0.53
Interest Received CFO
52.00
+39.41%
37.30
-21.14%
47.30
+747.67%
5.58
Issuance Of Capital Stock
0.00
0.00
-100.00%
583.70
+54.56%
377.64
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
Taxes Refund Paid
-18.40
-1050.00%
-1.60
-633.33%
0.30
-91.91%
3.71
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category